Silver Book Fact

It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%, in 2 years.  This means that 11,784 people would be spared blindness in that time period.

Bressler N, Doan Q, Varma R, Lee P, et al. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/427350

Reference

Title
Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration
Publication
Arch Ophthalmol
Publication Date
2011
Authors
Bressler N, Doan Q, Varma R, Lee P, et al
Volume & Issue
Volume 129, Issue 6
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%  
  • The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.  
  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…